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PCN10
COST OF HOSPITALIZATION FOR THORACIC 
SURGERY IN PATIENTS WITH LUNG CANCER
IN GREECE
Leftakis A1, Geitona M2
1Thoracic Diseases SOTIRIA Hospital, Athens, Greece; 
2National School of Public Health, Athens, Greece
OBJECTIVES: To estimate the cost of hospitalization for
thoracic surgery in patients with lung cancer, admitted to
the Intensive Care Unit (ICU) of “SOTIRIA” General
District Hospital in Athens.
METHODS: The chosen ICU is part of one of the largest
specialized thoracic disease hospitals in Greece. Methodol-
ogy is based on a retrospective study of patient records
over a six-month period from September 1st 1997 to Feb-
ruary 28th 1998. The sample consisted of 95 patients.
Clinical data were derived from patients’ medical records,
while administrative, economic and other data came from
the Hospital’s administrative/financial department. Cost
analysis is based on the cost of personnel, supplies, medi-
cation, laboratory and imaging tests, cost of infrastructure,
hotel services and various on-site costs. Descriptive statisti-
cal analysis and frequencies were determined for the age,
gender, hospital and length of stay (LOS-pre and postoper-
ative inpatient stay) in ICU, severity of illness, resource
consumption and ICU outcome (survival or death). All
costs are reported in 1998 US dollars.
RESULTS: 218 patients from the five “SOTIRIA” hospi-
tal surgical departments were admitted to the ICU, 95 of
whom (43.6%) were patients who underwent surgery for
lung cancer. They had a total of 2,011 inpatient days and
276 inpatient days in the ICU. LOS in the hospital was
21.1 days and 2.9 days in the ICU. LOS for the preopera-
tive period was 7.9 days and 10.3 days postoperative.
Total patient-hospitalization costs in the ICU are esti-
mated at US$ 191,065 (pre) and US$ 2,011(post) per pa-
tient. Major cost components are salaries of personnel
(41.7%), diagnostic tests (23%), and medication (15%).
Mean hospitalization cost for a thoracic surgery patient
with lung cancer is estimated at US$ 6,958.
CONCLUSIONS: Economic analysis could substantially
contribute to the costing of diseases and would enable
Greek policy makers to obtain the information required
for their decision-making.
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COST-EFFECTIVENESS OF SENTINEL LYMPH 
NODE MAPPING AND ADJUVANT INTERFERON 
THERAPY FOR STAGE II MELANOMA
Wilson LS, Reyes CM, Lu C, Lu M, Yen C
University of California San Francisco, San Francisco, CA, USA
OBJECTIVE: Clinical studies have demonstrated that
high dose adjuvant interferon therapy improves disease-
free and overall survival among high-risk (stage IIb and
stage III) melanoma patients. Sentinel lymph node map-
ping (SLM) identifies metastasis and more accurately dif-
ferentiates between stage II patients at high risk, who
then might benefit most from adjuvant interferon ther-
apy. We analyzed the cost-effectiveness of first testing
with sentinel lymph node mapping (SLM) and then treat-
ing with adjuvant interferon (IFN) therapy for stage II
melanoma.
METHODS: We used a decision analytic model to com-
pare four strategies for stage II patients after surgical ex-
cision of their melanoma: 1) treat all with low dose IFN;
2) test first with SLM and then treat only those with pos-
itive micrometastases with high dose IFN; 3) test first
with SLM and treat positives with high dose and nega-
tives with low dose IFN (test and treat appropriately); 4)
treat no one. Treatment, toxicity, follow-up and relapse
costs were included. The primary outcome was cost per
quality adjusted life year (QALY)
RESULTS: Our analyses show that it is cost-effective to
first test with SLM and treat appropriately compared to
treating all with low dose IFN ($12,400/QALY). More-
over, it is cost-effective to test and treat appropriately
versus testing and only treating some with high dose
($27,100/QALY). It is also more cost-effective to test and
treat appropriately compared to no treatment ($31,700/
QALY).
CONCLUSION: Appropriate dosing of IFN therapy
based on the results of sentinel lymph node mapping is a
cost-effective strategy for stage II melanoma patients.
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THE RELATIONSHIP OF AGE AND DURATION 
OF HORMONAL THERAPY USE AMONG 
PATIENTS DIAGNOSED WITH CANCER
OF THE PROSTATE
Stolshek B1, Hersom K2, Pelletier E2, Delgado D1
1Amgen, Inc, Thousand Oaks, CA; 2 The Lewin Group, San 
Francisco, CA
OBJECTIVE: The utilization of LHRH agonists and anti-
androgens in prostate cancer has resulted from both their
availability and the substantial regret of patients follow-
ing orchiectomy. Previously unavailable, this study de-
scribes hormonal therapy resource use by age group and
duration from a large payer claims database.
METHODS: Male patients were identified in the Synergy
data warehouse from 03/1999 to 07/2000 with age 40,
a claim for prostate cancer specific LHRH agonist medi-
cation, any additional prescription claim, and continuous
medical and pharmacy enrollment. New cases of LHRH
agonist monotherapy (MONO) or combination therapy
with anti-androgen (CAB) were defined as no MONO or
CAB during the 4 months prior to 3/1999. Therapy
groups were stratified by age group (65 (younger) and
65 (older)) and followed until 07/2000. Descriptive sta-
tistics were used to summarize the data.
RESULTS: 582 younger patients and 878 older patients
were identified. 93.0% of the younger patients had pri-
vate insurance compared to 28.2% government and
71.8% private insurance in the older patients. Average
